SK3530, a new anti-impotence drug, under clinical studies in UK.

Published: 2003-04-21 07:00:00

Updated: 2003-04-21 07:00:00

SK Chemical has developed SK3530, a new anti-impotence drug, jointly with In2Gen, a bio-venture company, and put its phase I clinical studies in England from April 23 after completing the pre-clinical studies on Mar. 31 and obtaining the phase I clinical study approval from the IRB (Institutional...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK